TY - JOUR
T1 - Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders
AU - Manchia, Mirko
AU - Isayeva, Ulker
AU - Collu, Roberto
AU - Primavera, Diego
AU - Deriu, Luca
AU - Caboni, Edoardo
AU - Iaselli, Maria Novella
AU - Sundas, Davide
AU - Tusconi, Massimo
AU - Pinna, Federica
AU - Paribello, Pasquale
AU - Scherma, Maria
AU - Pisanu, Claudia
AU - Meloni, Anna
AU - Zai, Clement C.
AU - Congiu, Donatella
AU - Squassina, Alessio
AU - Fratta, Walter
AU - Fadda, Paola
AU - Carpiniello, Bernardo
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/12
Y1 - 2022/12
N2 - Brain-derived neurotrophic factor (BDNF) is a key modulator of neuroplasticity and has an important role in determining the susceptibility to severe psychiatric disorder with a significant neurodevelopmental component such as major psychoses. Indeed, a potential association between BDNF serum levels and schizophrenia (SCZ) and schizoaffective disorder (SAD) has been tested in diverse studies and a considerable amount of them found reduced BDNF levels in these disorders. Here, we aimed at testing the association of BDNF serum levels with several demographic, clinical, and psychometric measures in 105 patients with SCZ and SAD, assessing the moderating effect of genetic variants within the BDNF gene. We also verified whether peripheral BDNF levels differed between patients with SCZ and SAD. Our findings revealed that BDNF serum levels are significantly lower in patients affected by SCZ and SAD presenting more severe depressive symptomatology. This finding awaits replication in future independent studies and points to BDNF as a possible prognostic indicator in major psychoses.
AB - Brain-derived neurotrophic factor (BDNF) is a key modulator of neuroplasticity and has an important role in determining the susceptibility to severe psychiatric disorder with a significant neurodevelopmental component such as major psychoses. Indeed, a potential association between BDNF serum levels and schizophrenia (SCZ) and schizoaffective disorder (SAD) has been tested in diverse studies and a considerable amount of them found reduced BDNF levels in these disorders. Here, we aimed at testing the association of BDNF serum levels with several demographic, clinical, and psychometric measures in 105 patients with SCZ and SAD, assessing the moderating effect of genetic variants within the BDNF gene. We also verified whether peripheral BDNF levels differed between patients with SCZ and SAD. Our findings revealed that BDNF serum levels are significantly lower in patients affected by SCZ and SAD presenting more severe depressive symptomatology. This finding awaits replication in future independent studies and points to BDNF as a possible prognostic indicator in major psychoses.
UR - http://www.scopus.com/inward/record.url?scp=85144661870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144661870&partnerID=8YFLogxK
U2 - 10.3390/brainsci12121666
DO - 10.3390/brainsci12121666
M3 - Article
C2 - 36552127
AN - SCOPUS:85144661870
SN - 2076-3425
VL - 12
JO - Brain Sciences
JF - Brain Sciences
IS - 12
M1 - 1666
ER -